Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract Cancer

NCT07745296 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

990

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Cancer (BTC)

Interventions

DRUG: Futibatinib
DRUG: Ivosidenib + Capecitabine
DRUG: Zanidatamab + Capecitabine
DRUG: Capecitabine (Xeloda)

Sponsor

UNICANCER